

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of Meir SHINITAN

Appln. No. 09/936,922

Date Filed: October 31, 2001

For: PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC...

Art Unit: 1617

Examiner: S. Wang

Washington, D.C.

Atty.'s Docket: SHINITZKY=5

OR

OR

Date: August 31, 2004

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, <u>Mail Stop Amendment</u> Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202 Confirmation No. 3023

Sir:

Transmitted herewith is a [X] AMENDMENT AND REMARKS in the above-identified application.

- Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted
- [] Applicant claims small entity status. See 37 C.F.R. §1.27.

[XX] No fee is required.

The fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)			
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS		
TOTAL	* 15	MINUS	** 20	0		
INDEP.	• 3	MINUS	*** 3	0		
FIRST PR	ESENTATION OF I	MULTIPLE (DEP. CLAIM			

_	SMALL ENTITY				
		RATE	ADDITIONAL FEE		
	x	9	\$		
	х	43	\$		
	+	145	\$		
ADDITIONAL FEE TOTAL			\$		

	OTHER THAN	AN SMALL ENTITY ADDITIONAL FEE				
	RATE					
X	18	\$				
×	86	\$				
+	290	\$				
	TOTAL	\$				

- If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- "If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity Response Filed Within			Other Than Small Entity Response Filed Within							
									[]	First
[]	Second	-	\$ 210.00		[]	Second	-	\$	420.00
[]	Third	-	\$ 475.00		[1	Third	-	\$	950.00
[]	Fourth	-	\$ 740.00		[]	Fourth	-	\$	1480.00
Month A	After Time	Peri	od Set		М	onth	After Time	Peri	od	Set
	ess fees (\$) already paid for	month(s) extension of time on						

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applican

She dan Neimark Registration No. 20,520

Facsimile: Telephone: (202) 737-3528 (202) 628-5197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTY.'S DOCKET: SHINITZKY =5

In re Application of:

Meir SHINITZKY

Date Filed: October 31, 2001

For: PHARMACEUTICAL COMPOSITIONS

COMPRISING CYCLIC...

Art Unit: 1617

Date Unit: 1617

Date Unit: 1617

Date Shinitzky

Mang

Confirmation No. 3023

Date Shinitzky

August 31, 2004

REPLY: AMENDMENT AND REMARKS

Honorable Commissioner for Patents U.S. Patent and Trademark Office 2011 South Clark Place Customer Window, Mail Stop AMENDMENT Crystal Plaza Two, Lobby, Room 1B03 Arlington, Virginia 22202

Sir:

Replying to the Office Action mailed July 28, 2004, please amend as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 8 of this paper.